Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 10/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572962 | 0.86 | ALDH1A1 (0.73) | HTTSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL4001716 | 0.84 | ALDH1A1 (0.75) | HTTSMN1; SMN2ALDH1A1MAPTPOLB | |
| SCHEMBL10192040 | 0.84 | GAA (0.67) | HTTSMN1; SMN2GAAMAPTPOLB | |
| SCHEMBL7282859 | 0.83 | ALDH1A1 (0.68) | HTTSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL29914686 | 0.82 | POLB (0.53) | HTTSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL3755148 | 0.82 | POLB (0.53) | HTTSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL21019394 | 0.81 | GAA (0.72) | HTTSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL22587392 | 0.81 | ALDH1A1 (0.66) | HTTSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL4010544 | 0.81 | SMN1; SMN2 (0.66) | HTTSMN1; SMN2ALDH1A1MAPTPOLB | |
| SCHEMBL29678260 | 0.81 | SMN1; SMN2 (0.66) | HTTSMN1; SMN2ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054431-A1 | BENZO-FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-0411751-A1 | Renin inhibitory peptides | Beecham Group p.l.c. (GB) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HTT 3147/4885SMN1; SMN2 3609/4885ALDH1A1 1497/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HTT 3147/4885SMN1; SMN2 3609/4885ALDH1A1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.